Antares Pharma, Inc. (ATRS)

[H2R]

SoS: "Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)"
https://smithonstocks.com/antares-pipeline-is-bursting-with-late-stage-products-atrs-2-77-buy/

It's a fairly long / well researched / thought out article and it's for subscribers, so I won't cut&paste the whole article. But here is the summary:

* Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next four years.

* I am projecting that revenues of five partnered products could increase from $17.0 million in 2016 to $142.0 million in 2021 (a nearly five fold increase) and that revenues from two wholly owned products could increase from $15.1 million in 2016 to $71.2 million in 2021 (an eight fold increase).

* The company has not unveiled other potential new products, but I think that there will be others. In my analysis, I do not attempt to attribute any value to them.

* My price target
** for 2017 is $4.10 to $5.75
** for 2018 is $5.50 to $7.60.

Lots of projections/assumptions/possible timeline, so to take with a grain of salt. At the same time, this pipeline has real possibilities.

Kind regards